gusperimus: Clinical Trials

5 trials of gusperimus, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated. 3 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23Completed 3
Not applicable1Terminated 1
Phase 11Completed 1
Phase 31Terminated 1

Follow gusperimus: new trials by email Literature Review of gusperimus trials Research Report on gusperimus

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis
Gusperimus + glucocorticoids, cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids - Wegeners Granulomatosis
Phase 3TerminatedNordic Pharma SAS42011-11-012015-05-29
Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection
Deoxyspergualin - Chronic Rejection
Not applicableTerminatedNippon Kayaku Co., Ltd.352009-06-012014-01-08
Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes
Allogeneic Pancreatic Islet Cells, Deoxyspergualin, Antithymocyte globulin - Diabetes Mellitus, Type 1
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)142006-10-012016-03-16
Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis
Gusperimus - Wegener's Granulomatosis
Phase 2CompletedNippon Kayaku Co., Ltd.452003-12-012017-03-06
Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis
NKT-01 - Lupus Nephritis
Phase 1 / Phase 2CompletedNippon Kayaku Co., Ltd.212003-10-012017-01-10

Conditions studied

Granulomatosis with Polyangiitis (2)  ·  Diabetes Mellitus, Type 1 (1)  ·  Hypoglycemia (1)  ·  Lupus Nephritis (1)  ·  Recurrence (1)  ·  Vasculitis (1)

Sponsors

Nippon Kayaku Co., Ltd. (3)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Nordic Pharma SAS (1)

Countries

Czechia (3)  ·  Germany (2)  ·  Denmark (1)  ·  Japan (1)  ·  Netherlands (1)  ·  Sweden (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Andrew Posselt, MD, PhD (1)  ·  Bernhard Hering, MD (1)  ·  David Jayne (1)  ·  David Jayne, MD (1)  ·  Hanns-Martin Lorenz, Professor (1)  ·  Hiroshi Harada, Chief (1)  ·  Xunrong Luo, MD, PhD (1)

Results publications

PMID 21356124